Earnings summaries and quarterly performance for GILEAD SCIENCES.
Executive leadership at GILEAD SCIENCES.
Daniel P. O’Day
Detailed
Chairman and Chief Executive Officer
CEO
AD
Andrew D. Dickinson
Detailed
Chief Financial Officer
DH
Deborah H. Telman
Detailed
Executive Vice President, Corporate Affairs and General Counsel
DB
Dietmar Berger
Detailed
Chief Medical Officer
EB
Erin Burkhart
Detailed
Senior Vice President, Controllership and Principal Accounting Officer
JM
Johanna Mercier
Detailed
Chief Commercial Officer
Board of directors at GILEAD SCIENCES.
Research analysts who have asked questions during GILEAD SCIENCES earnings calls.
TV
Tyler Van Buren
TD Cowen
7 questions for GILD
Also covers: ADVM, ALLO, ARGX +13 more
CB
Courtney Breen
AllianceBernstein
6 questions for GILD
Also covers: ABBV, AMGN, BMY +4 more
UR
Umer Raffat
Evercore ISI
6 questions for GILD
Also covers: ALKS, AMGN, BHC +15 more
Brian Abrahams
RBC Capital Markets
5 questions for GILD
Also covers: ACAD, ATAI, BCRX +19 more
Daina Graybosch
Leerink Partners
5 questions for GILD
Also covers: AFMD, BNTX, CGEN +6 more
Geoff Meacham
Citigroup Inc.
5 questions for GILD
Also covers: ABBV, AMGN, BMY +11 more
Michael Yee
Jefferies
5 questions for GILD
Also covers: ABBV, ALLO, AMGN +19 more
CL
Carter L. Gould
Barclays
4 questions for GILD
Also covers: ABBV, ALEC, AMGN +8 more
CS
Christopher Schott
JPMorgan Chase & Co.
4 questions for GILD
Also covers: ABBV, AMGN, AMRX +15 more
Mohit Bansal
Wells Fargo & Company
4 questions for GILD
Also covers: ABBV, AMGN, BMRN +16 more
Terence Flynn
Morgan Stanley
4 questions for GILD
Also covers: ABBV, AMGN, ARVN +17 more
ES
Evan Seigerman
BMO Capital Markets
3 questions for GILD
Also covers: ABBV, AMGN, ARVN +15 more
CS
Chris Schott
JPMorgan Chase & Company
2 questions for GILD
Also covers: ABBV, AMGN, BIIB +10 more
LC
Louise Chen
Cantor Fitzgerald
2 questions for GILD
Also covers: AMGN, ARDX, CNTB +18 more
Matthew Biegler
Oppenheimer & Co. Inc.
2 questions for GILD
Also covers: ALLO, ARVN, CTMX +2 more
Salveen Richter
Goldman Sachs
2 questions for GILD
Also covers: ACAD, AGIO, ALLO +21 more
TA
Tazeen Ahmad
Bank of America
2 questions for GILD
Also covers: ACAD, ALNY, APLS +22 more
TA
Timothy Anderson
BofA Securities
2 questions for GILD
Also covers: ABBV, AMGN, AZN +10 more
AH
Alexandria Hammond
Wolfe Research
1 question for GILD
Also covers: ABBV, AMGN, BIIB +7 more
C
Chris
Morgan Stanley
1 question for GILD
Also covers: MRNA, REGN, VRTX
EM
Eliana Merle
UBS
1 question for GILD
Also covers: ALNY, APLS, ARVN +17 more
Geoffrey Meacham
Citi
1 question for GILD
Also covers: ABBV, BIIB, BMY +6 more
JS
James Shin
Analyst
1 question for GILD
Also covers: ABBV, AMGN, AUTL +7 more
NG
Nicole Germino
Truist Securities
1 question for GILD
Also covers: CRIS, INSM, SGMO +1 more
Sadia
Wells Fargo & Company
1 question for GILD
SB
Simon Baker
Redburn Atlantic
1 question for GILD
Also covers: AUTL, AZN, BNTX +5 more
Recent press releases and 8-K filings for GILD.
Gilead Sciences reports positive phase 3 trial for bictegravir-lenacapavir pill
GILD
Product Launch
- A Lancet phase 3 trial found a once-daily bictegravir/lenacapavir tablet maintained viral suppression in 96% of long-term HIV patients, with no new resistance and fewer lipid side effects.
- ARTISTRY-1 and ARTISTRY-2 phase 3 studies confirmed the regimen is well tolerated and comparable to existing therapies, and Gilead plans to engage regulators for approval.
- The Yeztugo injectable lenacapavir showed near-perfect prevention efficacy (100% in PURPOSE1; 99.9% in PURPOSE2), prompting early trial stops and rapid commercial uptake.
- These clinical successes drove Gilead’s stock to multi-year highs and underscored its $182.5 billion market cap as it pivots toward ultra-long-acting HIV prevention.
2 days ago
Gilead announces Phase 3 trial results for bictegravir/lenacapavir regimen
GILD
- Gilead presented Phase 3 ARTISTRY-1 and ARTISTRY-2 data at CROI 2026 showing that the investigational once-daily single-tablet regimen of bictegravir 75 mg/lenacapavir 50 mg maintained virologic suppression in people with HIV switching therapy, with no new safety concerns identified.
- In ARTISTRY-1, BIC/LEN was noninferior to complex multi-tablet regimens at Week 48, with 0.8% vs 1.1% of participants having HIV-1 RNA ≥50 copies/mL, plus improved fasting lipids (–15 mg/dL vs +2 mg/dL) and a 7-point increase in treatment satisfaction.
- ARTISTRY-2 showed BIC/LEN was noninferior to BIKTARVY at Week 48, with 1.3% vs 1.0% of participants ≥50 copies/mL, stable CD4 counts, no capsid mutations, and similar drug-related adverse event rates (10.4% vs 12.0%).
- Gilead plans to leverage these results to support regulatory filings for the novel BIC/LEN combination.
2 days ago
LEO Pharma reports 2025 financial results
GILD
Earnings
Product Launch
Guidance Update
- LEO Pharma’s revenue rose 10% at constant exchange rates (8% in DKK) to DKK 13,499 million in 2025.
- Adjusted EBITDA more than doubled to DKK 2,107 million, delivering a 16% margin versus 7% in 2024.
- Net profit turned positive at DKK 2,489 million and free cash flow improved to DKK 1,875 million.
- Portfolio expanded with the launch of Anzupgo® in the U.S. and the addition of Spevigo®, backed by new strategic partnerships.
Feb 18, 2026, 8:00 AM
Gilead Sciences reports strong Q4 and issues 2026 guidance
GILD
Earnings
Guidance Update
- Gilead ended 2025 with $28.9 billion in product sales and a 6% year-over-year HIV sales increase, driven by Biktarvy’s $4.0 billion and Descovy’s $819 million in Q4.
- The newly launched HIV-prevention injection Yeztugo posted $96 million in Q4 and is forecast for $800 million in 2026, below some investor expectations.
- Q4 cash metrics included $10.6 billion in cash and equivalents, $3.3 billion in operating cash flow, $1.0 billion in dividends paid and $230 million in share repurchases.
- For 2026, Gilead expects $29.6 billion–$30.0 billion in product sales and $8.45–$8.85 in non-GAAP EPS.
- Upcoming 2026 pipeline milestones span Phase 3 readouts and launches for Trodelvy P3 EVOKE-03, ASCENT-GYN, BIC/LEN, ISL/LEN and anito-cel in 2H26, plus an FDA decision on bulevirtide in 1H26.
Feb 10, 2026, 10:03 PM
Gilead Sciences reports Q4 2025 results and 2026 guidance
GILD
Earnings
Guidance Update
Product Launch
- Full-year 2025 total product sales were $28.9 billion (up 1% vs. 2024), with base business revenue of $28 billion (+4%), driven by 6% HIV sales growth to $20.8 billion; non-GAAP diluted EPS was $8.15.
- Q4 2025 product sales reached $7.9 billion (+5% YoY; +7% ex-Veklury), and non-GAAP EPS was $1.86.
- 2026 guidance: total product sales of $29.6 billion–$30 billion; base business up 4–5%; HIV sales +6% (Yeztugo revenue ~ $800 million); cell therapy revenues down ~ 10%.
- Pipeline and launches: four planned 2026 commercial launches—Trodelvy in first-line metastatic TNBC, daily oral bictegravir + lenacapavir for HIV, anito-cel in multiple myeloma, and bulevirtide for hepatitis D—and 53 ongoing clinical programs with five pivotal readouts expected in 2026.
Feb 10, 2026, 9:30 PM
Gilead Sciences reports Q4 2025 results
GILD
Earnings
Guidance Update
Product Launch
- Gilead delivered Q4 total product sales of $7.9 B, up 5% YoY (base business $7.7 B, +7% YoY), driven by HIV ($5.8 B, +6% YoY) and Liver Disease ($844 M, +17% YoY).
- For FY25, base business sales reached $28.0 B, +4% YoY (+8% ex-Part D redesign), with total product sales of $28.9 B, +1% YoY (+5% ex-Part D redesign).
- Q4 non-GAAP diluted EPS was $1.86, down 2% YoY, and non-GAAP operating income was $3.09 B, down 1% YoY.
- FY26 guidance projects total product sales of $29.6–30.0 B and non-GAAP diluted EPS of $8.45–8.85.
- Key 2026 milestones include Phase 3 updates for ISLEND-1/-2 in 1H26 and multiple FDA decisions—BIC/LEN, ASCENT-03/04, EVOKE-03—in 2H26, supporting future growth.
Feb 10, 2026, 9:30 PM
Gilead Sciences reports Q4 2025 results
GILD
Earnings
Guidance Update
Product Launch
- Q4 2025 total product sales were $7.9 billion (+5% YoY; ex-Veklury $7.7 billion, +7% YoY), and full-year 2025 sales were $28.9 billion (+1% YoY; base business ex-Veklury $28 billion, +4% YoY)
- 2025 HIV sales reached $20.8 billion, up 6% YoY (10% YoY ex–Medicare Part D headwind), with Q4 HIV revenue of $5.8 billion, +6% YoY
- Gilead plans four new commercial launches in 2026 and up to 10 by 2027 across HIV, oncology, and liver disease (e.g., Trodelvy first-line metastatic TNBC, bictegravir + lenacapavir oral combo, Anito-cel, bulevirtide), supported by five Phase III readouts
- 2026 guidance targets $29.6 – 30 billion in total product sales, $29 – 29.4 billion in base business sales (+4 – 5% YoY), and non-GAAP diluted EPS of $8.45 – 8.85 per share
Feb 10, 2026, 9:30 PM
Gilead Sciences reports Q4 2025 results
GILD
Earnings
Guidance Update
- FY2025 product sales were $28.9 billion, up 1% YoY; base business revenue was $28 billion, up 4%, after $1.1 billion Part D and $900 million Veklury headwinds.
- Full-year segment sales: HIV $20.8 billion (+6%), liver $3.2 billion (+6%), Veklury $911 million (–49%).
- Q4 2025 product sales reached $7.9 billion (+5% YoY; +7% ex-Veklury) and non-GAAP EPS was $1.86 vs $1.90 a year ago.
- 2026 guidance: total product sales $29.6–30 billion; base business $29–29.4 billion (+4–5%); non-GAAP EPS $8.45–8.85.
- HIV & prevention outlook: 2026 HIV sales expected +6% (–2% policy headwinds) ; Sunlenca revenue ~$800 million (vs $150 million in 2025) ; Yes2Go revenue ~$800 million.
Feb 10, 2026, 9:30 PM
Gilead Sciences announces Q4 and full‐year 2025 financial results
GILD
Earnings
Guidance Update
Dividends
- Q4 2025 revenues rose 5% to $7.9 B, with diluted EPS of $1.74 (vs. $1.42 in Q4 2024)
- Full-year 2025 revenues increased 2% to $29.4 B, delivering diluted EPS of $6.78 (vs. $0.38 in 2024)
- Product sales excluding Veklury grew 4% to $28.0 B for FY 2025, led by Biktarvy sales up 7% to $14.3 B
- Generated $3.3 B of operating cash flow in Q4, held $10.6 B in cash and marketable securities at year-end, and returned capital via $1.0 B of dividends and $230 M of share repurchases in Q4 2025
- For 2026, expects product sales of $29.6–30.0 B, diluted EPS of $6.75–7.15, and non-GAAP EPS of $8.45–8.85
Feb 10, 2026, 9:02 PM
Gilead Sciences reports Q4 and FY 2025 results
GILD
Earnings
Dividends
Share Buyback
- Q4 2025 revenue rose 5% to $7.9 billion; diluted EPS was $1.74, up from $1.42 in Q4 2024.
- Full-year 2025 revenue increased 2% to $29.4 billion, with product sales up 1% to $28.9 billion; diluted EPS surged to $6.78 from $0.38 in 2024.
- Ended 2025 with $10.6 billion in cash and equivalents; Q4 operating cash flow was $3.3 billion, while $1.0 billion was returned in dividends and $230 million in share repurchases.
Feb 10, 2026, 9:01 PM
Fintool News
In-depth analysis and coverage of GILEAD SCIENCES.
Quarterly earnings call transcripts for GILEAD SCIENCES.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more